Dermata Therapeutics Inc (DRMA)vsBeiGene, Ltd. (ONC)
DRMA
Dermata Therapeutics Inc
$1.55
-1.27%
HEALTHCARE · Cap: $4.67M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. DRMA trades at a lower P/E of 0.1x. ONC earns a higher WallStSmart Score of 42/100 (D).
DRMA
Avoid23
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+98.6%
Fair Value
$103.63
Current Price
$1.55
$102.08 discount
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : DRMA
The strongest argument for DRMA centers on P/E Ratio, Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
DRMA profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
DRMA carries more volatility with a beta of 0.60 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 23/100) and 32.8% revenue growth. DRMA offers better value entry with a 98.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead asset, DMT310, which utilizes a novel delivery system to improve treatment efficacy for acne and other skin disorders. The company is committed to addressing significant unmet needs in the dermatology market with a strategically designed pipeline aimed at advancing skin health. As Dermata navigates its clinical trials, it leverages proprietary technology to create effective, safe, and user-friendly therapeutic solutions that position it for leadership in the dermatological arena. With a strong emphasis on patient outcomes, Dermata is poised to make a meaningful impact in the treatment of skin-related issues.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?